四環醫藥(00460.HK)附屬獲授予琥珀酸美托洛爾緩釋片在內地推廣權
四環醫藥(00460.HK)公布,附屬公司海南四環醫藥司與佛山德芮可製藥簽訂了有關琥珀酸美托洛爾緩釋片23.75mg/47.5mg/95mg/190mg產品總營銷服務協議。
根據該協議,德芮可向集團授予該產品於中國大陸地區之產品獨家市場推廣權。推廣權期限為該產品任一劑量取得中國國家藥品監督管理局(NMPA)藥物註冊批件和╱或上市許可之日起滿5年。集團於該協議期滿後擁有同等條件下的優先續約權。
根據中國米內資料庫統計,琥珀酸美托洛爾緩釋片於2018年中國城市公立醫院之銷售額約為13億元人民幣。目前市場上除了阿斯利康的原研產品獨家在售外,尚無仿製藥獲批。此次集團所代理的該產品目前處於優先評審階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.